Kairos Pharma’s (KAPA) “Buy” Rating Reiterated at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 target price on the stock.

Kairos Pharma Trading Up 3.1 %

Kairos Pharma stock opened at $1.01 on Thursday. The business has a fifty day simple moving average of $1.34. Kairos Pharma has a 52 week low of $0.85 and a 52 week high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.